COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

Research Shows That Decoys Can be Effective in Neutralizing SARS-CoV-2

Clinical laboratories and meta-analysis recently published casts doubts on serology test performance, Abbott antigen test
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

COVID-19 related research creates new technological advances that could have a lasting impact on medical science

Interesting research that may have an impact beyond just the COVID-19 pandemic uses decoys that may neutralize the SARS-CoV-2 virus. This strategy uses molecules that tightly and irreversibly bind to the sites of the virus that would normally bind to cells while infecting them. By tricking the virus into binding onto molecules that are similar to cell binding sites, the virus can effectively be prohibited from binding onto cells and causing infection.

Research into this possibility began in the late summer of 2020 but continues today. Use of this technology could be preventive, administered to people before they have an infection and to keep the virus from starting to enter cells and causing an infection. Even though COVID-19 vaccines are now available and are the best choice for preventing infection, the ongoing research in this area could still reduce infections of COVID-19 and lead to advances in preventing other diseases.

Potential to Block Viral Infection

This technology could also be used to lessen the severity of infections by reducing the active viral load early in infections. This approach could be used as an early intervention to reduce the infection among people who have tested positive, but arent yet suffering symptoms. But we also see this as part of a larger antiviral strategy,” said Robert Linhardt, PhD, Professor of Chemistry and Chemical Biology at Rensselaer Polytechnic Institute. There are many ways to combat a virus, and as weve seen with HIV, with the right combination of therapies, we can control the disease.”

Linhardt’s research found that the blood thinner heparin binds to SARS-CoV-2 spike proteins at 73 picomoles, a measure of the interaction between the two molecules. Thats exceptional, extremely tight binding,” said Jonathan Dordick, PhD, a chemical and biological engineering professor at Rensselaer who is collaborating with Linhardt to develop the decoy strategy. Its hundreds of thousands of times tighter than a typical antibody antigen. Once it binds, its not going to come off.”

Linhardt’s research has also included other molecules that show similar promise. One molecule, an extract from edible seaweed, showed a substantially higher level of effectiveness than remdesivir, an antiviral used to combat COVID-19, or than heparin.

SARS-CoV-2 Virus Research Offers Larger Benefits

While this research has shown significant promise in treating or preventing COVID-19, it also has potential applications to many other viral infections. This isnt the only virus that were going to confront in a pandemic,” Dordick explained. We dont really have great antivirals, but this is a pathway forward. We need to be in a position where we understand how things like heparin and related compounds can block virus entry.”

What interests us is a new way of getting at infection,” Robert Linhardt expanded. The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”

Its a very complicated mechanism that we quite frankly dont know all the details about, but were getting more information,” said Dordick. One thing thats become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.”

While this research was first started last year, it continues to be developed. A paper published in early March of 2021 presented research that showed that heparin not only binds to SARS-CoV-2 but also changes its receptors upon binding.

Advances in this area of research have implications for many viruses beyond SARS-CoV-2. As this technology becomes better understood, it seems possible that it may one day be used to treat influenza, other existing coronaviruses, or even, potentially, viruses that have yet to emerge.

While the COVID-19 pandemic has caused some devastating effects on public health, it has also led to several innovations that may contribute to medical science in the years to come. Clinical laboratories will benefit from keeping current with the emerging technological advances that rise out of the pandemic response.

—By Caleb Williams, Editor, STAT Intelligence Briefings

Related Resources:

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group